Schiff Hardin issued the following announcement on Sept. 05.
Intellectual Property Practice Group Co-Leader Imron Aly has joined the advisory board for the Center for Biosimilars, an online resource for emerging pharmaceutical biotechnology that discusses the current landscape for advanced health care management with top industry thought leaders.
The board is composed of highly respected authorities in the biosimilars and healthcare industries, including health economics experts, pharmacists, managed care professionals, and key clinical specialists.
The Center for Biosimilars has featured Aly’s insights on important industry trends, such as “Pay-for-Delay,” drug prices, the Federal Drug Administration’s Purple Book, patent litigation, and inter partes review.
Original source can be found here.